nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—SLC6A3—nerve—amyotrophic lateral sclerosis	0.0164	0.0387	CbGeAlD
Methamphetamine—SLC18A1—nervous system—amyotrophic lateral sclerosis	0.0153	0.036	CbGeAlD
Methamphetamine—SLC22A3—tongue—amyotrophic lateral sclerosis	0.0151	0.0356	CbGeAlD
Methamphetamine—SLC18A1—central nervous system—amyotrophic lateral sclerosis	0.0147	0.0346	CbGeAlD
Methamphetamine—TAAR1—nervous system—amyotrophic lateral sclerosis	0.0143	0.0338	CbGeAlD
Methamphetamine—MAOB—nerve—amyotrophic lateral sclerosis	0.0143	0.0337	CbGeAlD
Methamphetamine—TAAR1—central nervous system—amyotrophic lateral sclerosis	0.0138	0.0326	CbGeAlD
Methamphetamine—SLC6A2—nerve—amyotrophic lateral sclerosis	0.0132	0.0312	CbGeAlD
Methamphetamine—SLC6A3—hindbrain—amyotrophic lateral sclerosis	0.0123	0.029	CbGeAlD
Methamphetamine—MAOA—nerve—amyotrophic lateral sclerosis	0.0122	0.0287	CbGeAlD
Methamphetamine—ADRA2A—peripheral nervous system—amyotrophic lateral sclerosis	0.012	0.0283	CbGeAlD
Methamphetamine—SLC18A1—brain—amyotrophic lateral sclerosis	0.0117	0.0275	CbGeAlD
Methamphetamine—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.0113	0.0265	CbGeAlD
Methamphetamine—MAOB—hindbrain—amyotrophic lateral sclerosis	0.0107	0.0252	CbGeAlD
Methamphetamine—SLC18A2—brainstem—amyotrophic lateral sclerosis	0.00931	0.0219	CbGeAlD
Methamphetamine—MAOA—hindbrain—amyotrophic lateral sclerosis	0.00913	0.0215	CbGeAlD
Methamphetamine—SLC22A3—embryo—amyotrophic lateral sclerosis	0.00723	0.017	CbGeAlD
Methamphetamine—SLC6A3—brainstem—amyotrophic lateral sclerosis	0.00704	0.0166	CbGeAlD
Methamphetamine—MAOB—embryo—amyotrophic lateral sclerosis	0.00669	0.0158	CbGeAlD
Methamphetamine—SLC18A2—medulla oblongata—amyotrophic lateral sclerosis	0.00649	0.0153	CbGeAlD
Methamphetamine—SLC6A4—brainstem—amyotrophic lateral sclerosis	0.00645	0.0152	CbGeAlD
Methamphetamine—MAOB—brainstem—amyotrophic lateral sclerosis	0.00613	0.0145	CbGeAlD
Methamphetamine—MAOA—embryo—amyotrophic lateral sclerosis	0.00571	0.0135	CbGeAlD
Methamphetamine—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.00568	0.0134	CbGeAlD
Methamphetamine—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00542	0.0128	CbGeAlD
Methamphetamine—MAOA—brainstem—amyotrophic lateral sclerosis	0.00523	0.0123	CbGeAlD
Methamphetamine—SLC18A2—nervous system—amyotrophic lateral sclerosis	0.00488	0.0115	CbGeAlD
Methamphetamine—SLC18A2—central nervous system—amyotrophic lateral sclerosis	0.00469	0.0111	CbGeAlD
Methamphetamine—SLC18A2—cerebellum—amyotrophic lateral sclerosis	0.00459	0.0108	CbGeAlD
Methamphetamine—SLC6A3—spinal cord—amyotrophic lateral sclerosis	0.00438	0.0103	CbGeAlD
Methamphetamine—MAOB—medulla oblongata—amyotrophic lateral sclerosis	0.00428	0.0101	CbGeAlD
Methamphetamine—SLC6A4—spinal cord—amyotrophic lateral sclerosis	0.00401	0.00945	CbGeAlD
Methamphetamine—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.00396	0.00933	CbGeAlD
Methamphetamine—MAOB—spinal cord—amyotrophic lateral sclerosis	0.00381	0.00899	CbGeAlD
Methamphetamine—SLC18A2—brain—amyotrophic lateral sclerosis	0.00373	0.00879	CbGeAlD
Methamphetamine—SLC6A3—nervous system—amyotrophic lateral sclerosis	0.00369	0.00869	CbGeAlD
Methamphetamine—MAOA—medulla oblongata—amyotrophic lateral sclerosis	0.00365	0.0086	CbGeAlD
Methamphetamine—SLC6A3—central nervous system—amyotrophic lateral sclerosis	0.00355	0.00837	CbGeAlD
Methamphetamine—ADRA2C—medulla oblongata—amyotrophic lateral sclerosis	0.00351	0.00827	CbGeAlD
Methamphetamine—SLC22A3—nervous system—amyotrophic lateral sclerosis	0.00347	0.00819	CbGeAlD
Methamphetamine—SLC6A3—cerebellum—amyotrophic lateral sclerosis	0.00347	0.00818	CbGeAlD
Methamphetamine—SLC6A4—nervous system—amyotrophic lateral sclerosis	0.00338	0.00797	CbGeAlD
Methamphetamine—SLC22A5—medulla oblongata—amyotrophic lateral sclerosis	0.00336	0.00792	CbGeAlD
Methamphetamine—SLC22A3—central nervous system—amyotrophic lateral sclerosis	0.00334	0.00788	CbGeAlD
Methamphetamine—SLC6A4—central nervous system—amyotrophic lateral sclerosis	0.00325	0.00767	CbGeAlD
Methamphetamine—MAOA—spinal cord—amyotrophic lateral sclerosis	0.00325	0.00767	CbGeAlD
Methamphetamine—MAOB—nervous system—amyotrophic lateral sclerosis	0.00321	0.00757	CbGeAlD
Methamphetamine—ADRA2C—spinal cord—amyotrophic lateral sclerosis	0.00313	0.00737	CbGeAlD
Methamphetamine—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00311	0.00733	CbGeAlD
Methamphetamine—MAOB—central nervous system—amyotrophic lateral sclerosis	0.00309	0.00729	CbGeAlD
Methamphetamine—MAOB—cerebellum—amyotrophic lateral sclerosis	0.00302	0.00713	CbGeAlD
Methamphetamine—SLC22A5—spinal cord—amyotrophic lateral sclerosis	0.003	0.00706	CbGeAlD
Methamphetamine—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.00298	0.00701	CbGeAlD
Methamphetamine—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.00286	0.00675	CbGeAlD
Methamphetamine—SLC6A3—brain—amyotrophic lateral sclerosis	0.00282	0.00665	CbGeAlD
Methamphetamine—ADRA2A—medulla oblongata—amyotrophic lateral sclerosis	0.0028	0.0066	CbGeAlD
Methamphetamine—MAOA—nervous system—amyotrophic lateral sclerosis	0.00274	0.00646	CbGeAlD
Methamphetamine—SLC22A3—brain—amyotrophic lateral sclerosis	0.00265	0.00626	CbGeAlD
Methamphetamine—MAOA—central nervous system—amyotrophic lateral sclerosis	0.00264	0.00622	CbGeAlD
Methamphetamine—ADRA2C—nervous system—amyotrophic lateral sclerosis	0.00264	0.00621	CbGeAlD
Methamphetamine—SLC6A4—brain—amyotrophic lateral sclerosis	0.00258	0.00609	CbGeAlD
Methamphetamine—MAOA—cerebellum—amyotrophic lateral sclerosis	0.00258	0.00608	CbGeAlD
Methamphetamine—ADRA2C—central nervous system—amyotrophic lateral sclerosis	0.00254	0.00598	CbGeAlD
Methamphetamine—ADRA2A—spinal cord—amyotrophic lateral sclerosis	0.0025	0.00588	CbGeAlD
Methamphetamine—ADRA2C—cerebellum—amyotrophic lateral sclerosis	0.00248	0.00585	CbGeAlD
Methamphetamine—MAOB—brain—amyotrophic lateral sclerosis	0.00246	0.00579	CbGeAlD
Methamphetamine—SLC22A5—cerebellum—amyotrophic lateral sclerosis	0.00238	0.0056	CbGeAlD
Methamphetamine—SLC6A2—brain—amyotrophic lateral sclerosis	0.00227	0.00536	CbGeAlD
Methamphetamine—ADRA2A—nervous system—amyotrophic lateral sclerosis	0.0021	0.00496	CbGeAlD
Methamphetamine—MAOA—brain—amyotrophic lateral sclerosis	0.0021	0.00494	CbGeAlD
Methamphetamine—ADRA2A—central nervous system—amyotrophic lateral sclerosis	0.00202	0.00477	CbGeAlD
Methamphetamine—ADRA2C—brain—amyotrophic lateral sclerosis	0.00201	0.00475	CbGeAlD
Methamphetamine—ADRA2A—cerebellum—amyotrophic lateral sclerosis	0.00198	0.00467	CbGeAlD
Methamphetamine—SLC22A5—brain—amyotrophic lateral sclerosis	0.00193	0.00455	CbGeAlD
Methamphetamine—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.00163	0.00384	CbGeAlD
Methamphetamine—ADRA2A—brain—amyotrophic lateral sclerosis	0.00161	0.00379	CbGeAlD
Methamphetamine—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.00157	0.0037	CbGeAlD
Methamphetamine—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.00153	0.00361	CbGeAlD
Methamphetamine—CYP2D6—brain—amyotrophic lateral sclerosis	0.00125	0.00294	CbGeAlD
Methamphetamine—MAOB—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000791	0.00137	CbGpPWpGaD
Methamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000785	0.00136	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000763	0.00133	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000761	0.00132	CbGpPWpGaD
Methamphetamine—SLC6A3—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000751	0.0013	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.00075	0.0013	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.00075	0.0013	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000748	0.0013	CbGpPWpGaD
Methamphetamine—SLC6A3—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000742	0.00129	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000737	0.00128	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000736	0.00128	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000732	0.00127	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000732	0.00127	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000719	0.00125	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000709	0.00123	CbGpPWpGaD
Methamphetamine—MAOA—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000708	0.00123	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000692	0.0012	CbGpPWpGaD
Methamphetamine—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000689	0.0012	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000687	0.00119	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.000686	0.00119	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.000678	0.00118	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000672	0.00117	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00067	0.00116	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000669	0.00116	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000649	0.00113	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000649	0.00113	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000647	0.00112	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000647	0.00112	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—DAO—amyotrophic lateral sclerosis	0.000626	0.00109	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000622	0.00108	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.000619	0.00108	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.00061	0.00106	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000603	0.00105	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000594	0.00103	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000585	0.00102	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.000579	0.001	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000578	0.001	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000577	0.001	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000576	0.001	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000558	0.000969	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000548	0.000951	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000546	0.000947	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000543	0.000943	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000543	0.000943	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000538	0.000934	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—DAO—amyotrophic lateral sclerosis	0.000529	0.000919	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000526	0.000914	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	0.000523	0.000908	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000521	0.000905	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000511	0.000888	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000505	0.000877	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000505	0.000877	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000504	0.000876	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000497	0.000862	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000491	0.000852	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	0.000489	0.000848	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000474	0.000823	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.00047	0.000816	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	0.000469	0.000815	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000462	0.000802	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.00045	0.000782	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000449	0.000781	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000447	0.000777	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000447	0.000777	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000447	0.000776	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000447	0.000776	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000446	0.000774	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	0.000438	0.000761	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—GSR—amyotrophic lateral sclerosis	0.000437	0.00076	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000437	0.000759	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000434	0.000754	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000423	0.000735	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000415	0.000721	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000414	0.00072	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000408	0.000709	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000401	0.000697	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000399	0.000692	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	0.000397	0.000689	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000395	0.000686	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—DAO—amyotrophic lateral sclerosis	0.000393	0.000682	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000389	0.000675	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000381	0.000662	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00038	0.000659	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.00037	0.000643	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GSR—amyotrophic lateral sclerosis	0.00037	0.000643	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000369	0.00064	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000368	0.00064	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000363	0.00063	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000363	0.00063	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000359	0.000624	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000357	0.00062	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	0.000356	0.000618	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000332	0.000576	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—DAO—amyotrophic lateral sclerosis	0.000323	0.000561	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	0.000319	0.000554	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000317	0.00055	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000314	0.000545	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000313	0.000543	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000309	0.000537	CbGpPWpGaD
Methamphetamine—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000308	0.000536	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000308	0.000536	CbGpPWpGaD
Methamphetamine—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000304	0.000528	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000304	0.000528	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000299	0.00052	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000298	0.000517	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	0.000298	0.000517	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000297	0.000517	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000293	0.000509	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00029	0.000504	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000289	0.000502	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000281	0.000488	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GSR—amyotrophic lateral sclerosis	0.000275	0.000477	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.00027	0.000468	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.000263	0.000457	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000262	0.000456	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—DAO—amyotrophic lateral sclerosis	0.000262	0.000455	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.000252	0.000437	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.000245	0.000426	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000245	0.000425	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	0.000242	0.00042	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000242	0.00042	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000239	0.000415	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000238	0.000414	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000236	0.00041	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000236	0.00041	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000235	0.000409	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000235	0.000408	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000226	0.000392	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GSR—amyotrophic lateral sclerosis	0.000226	0.000392	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000225	0.000392	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000223	0.000388	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000219	0.00038	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000216	0.000375	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000213	0.00037	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	0.000208	0.000362	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000206	0.000358	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000205	0.000355	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.000205	0.000355	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	0.000203	0.000352	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000201	0.000349	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000199	0.000345	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000195	0.000339	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	0.000195	0.000338	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000193	0.000335	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000192	0.000334	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000189	0.000328	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000189	0.000328	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000185	0.000322	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000183	0.000319	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GSR—amyotrophic lateral sclerosis	0.000183	0.000319	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000182	0.000317	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000181	0.000315	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000177	0.000308	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000177	0.000307	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	0.000171	0.000297	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000168	0.000292	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000166	0.000289	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000166	0.000288	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—IGF1—amyotrophic lateral sclerosis	0.000164	0.000286	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000163	0.000284	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	0.000158	0.000275	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000157	0.000272	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000156	0.000271	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	0.000156	0.000271	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000155	0.000269	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—IGF1—amyotrophic lateral sclerosis	0.000154	0.000267	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000151	0.000262	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.00015	0.000261	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000148	0.000257	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	0.000147	0.000256	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—APOE—amyotrophic lateral sclerosis	0.000146	0.000254	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000143	0.000249	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000139	0.000241	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000135	0.000235	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	0.000132	0.00023	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.00013	0.000225	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00013	0.000225	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000127	0.000221	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000126	0.000219	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000126	0.000219	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—IGF1—amyotrophic lateral sclerosis	0.000125	0.000217	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—APOE—amyotrophic lateral sclerosis	0.000124	0.000215	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000123	0.000213	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000121	0.00021	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	0.00012	0.000208	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000115	0.000199	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000114	0.000198	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000111	0.000193	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—VEGFA—amyotrophic lateral sclerosis	0.000107	0.000186	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000107	0.000186	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000107	0.000185	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000105	0.000183	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000102	0.000178	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000102	0.000177	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—VEGFA—amyotrophic lateral sclerosis	0.0001	0.000174	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.0001	0.000174	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	0.0001	0.000174	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	9.99e-05	0.000174	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.97e-05	0.000173	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	9.81e-05	0.00017	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.52e-05	0.000165	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	9.31e-05	0.000162	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—APOE—amyotrophic lateral sclerosis	9.16e-05	0.000159	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.16e-05	0.000159	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.72e-05	0.000151	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	8.65e-05	0.00015	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.46e-05	0.000147	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	8.2e-05	0.000142	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—VEGFA—amyotrophic lateral sclerosis	8.15e-05	0.000141	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.15e-05	0.000141	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	8.12e-05	0.000141	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—TP53—amyotrophic lateral sclerosis	8.11e-05	0.000141	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.09e-05	0.000141	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	7.73e-05	0.000134	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.66e-05	0.000133	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—TP53—amyotrophic lateral sclerosis	7.58e-05	0.000132	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—APOE—amyotrophic lateral sclerosis	7.54e-05	0.000131	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.44e-05	0.000129	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—C3—amyotrophic lateral sclerosis	7.25e-05	0.000126	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.77e-05	0.000118	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.75e-05	0.000117	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	6.62e-05	0.000115	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.3e-05	0.000109	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.28e-05	0.000109	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	6.22e-05	0.000108	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TP53—amyotrophic lateral sclerosis	6.16e-05	0.000107	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—APOE—amyotrophic lateral sclerosis	6.12e-05	0.000106	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.57e-05	9.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.5e-05	9.55e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.27e-05	9.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.21e-05	9.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.16e-05	8.97e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.12e-05	8.89e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.85e-05	8.42e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.29e-05	7.45e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.23e-05	7.34e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.19e-05	7.28e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.05e-05	7.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.01e-05	6.96e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	3.99e-05	6.93e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.79e-05	6.58e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.64e-05	6.32e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.4e-05	5.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.26e-05	5.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.08e-05	5.34e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.76e-05	4.8e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.75e-05	4.78e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.73e-05	4.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.57e-05	4.46e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.09e-05	3.62e-05	CbGpPWpGaD
